Revia
In brief
- Revia (naltrexone) is classified as a prescription-only medicine in most regions (USA, EU, Australia), but availability varies — some local pharmacies or online suppliers may supply Revia without a prescription or receipt; check local regulations and legal risks before purchasing.
- Revia is used for relapse prevention in opioid use disorder and for treating alcohol dependence; it is an opioid receptor antagonist (primarily a competitive mu‑opioid receptor blocker) that reduces the rewarding effects of opioids and alcohol cravings.
- The usual adult dose is 50 mg orally once daily for alcohol or opioid relapse prevention; the extended‑release intramuscular formulation is 380 mg once every 4 weeks.
- Administration forms are oral film‑coated scored tablets (50 mg) and a prolonged‑release intramuscular injection (380 mg vial for IM use after reconstitution).
- Oral tablets begin to take effect within about 30–60 minutes (peak concentrations ~1 hour); the depot injection produces clinical blockade within hours as levels rise.
- A single oral dose provides opioid receptor blockade for roughly 24 hours; the extended‑release injection is effective for about 4 weeks per dose.
- Alcohol warning: naltrexone is used to reduce alcohol cravings but can cause hepatotoxicity—avoid heavy or binge drinking, do not start during acute alcohol withdrawal or if you have acute hepatitis, and have liver function monitored regularly.
- The most common side effect is nausea; other frequent effects include headache, insomnia, joint or muscle pain, anxiety, fatigue and reduced appetite.
- Would you like to try “revia” without a prescription?
Critical Warnings & Restrictions (Safety First) — Patient Protection, Australian Context
Basic Revia Information
- INN (International Nonproprietary Name): Naltrexone hydrochloride
- Brand Names Available In Australia: Revia (50 mg tablets, brand discontinued in many regions; generics available), Vivitrol (380 mg injectable, available), Depade (discontinued in some markets), Naltrexona (generic formulations seen internationally)
- ATC Code: N07BB04
- Forms & Dosages: Tablet 50 mg oral; prolonged‑release injection 380 mg intramuscular (powder for reconstitution)
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: Prescription Only (Rx)
High-Risk Groups
Who is at greatest risk when starting naltrexone?
Do not start naltrexone if the patient is currently taking opioids or has used them within the last 7–10 days.
Starting in that situation can trigger precipitated opioid withdrawal.
Absolute contraindications include acute hepatitis or liver failure and known hypersensitivity to naltrexone or excipients.
Pregnancy risk must be individually assessed and specialist advice sought for breastfeeding.
Elderly patients require close monitoring of hepatic and renal function.
Adolescents under 18 are not recommended because safety and effectiveness are not established.
People with a history of depression or suicidal ideation need careful monitoring because of increased risk.
- Checklist At Point‑Of‑Care For Prescribers/Pharmacists:
- Baseline liver function tests (LFTs).
- Detailed opioid history and confirmation of opioid‑free interval (7–10 days where relevant).
- Mental health screen for depression and suicidal ideation.
- Pregnancy test for women of childbearing potential if clinically relevant.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Can naltrexone affect your ability to drive or work in safety‑critical roles?
Naltrexone may cause fatigue, dizziness or sleep disturbance in some people.
If you feel drowsy, dizzy or otherwise impaired, do not drive or operate heavy machinery.
Employers and employees in safety‑critical industries such as aviation, heavy‑vehicle driving and mining should consult workplace policy and Safe Work Australia guidance.
Consider occupational restrictions if naltrexone causes impairment sufficient to affect safety‑critical performance.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking naltrexone?
A: Most people can drive.
A: If you feel drowsy, dizzy or impaired, do not drive or operate machinery.
A: Inform your employer if you work in a safety‑critical role and follow local workplace rules and Safe Work Australia guidance.
A: When in doubt, discuss driving safety with your GP or pharmacist.
Usage Basics
INN, Brand Names And Availability (Australian Framing)
What names will you see for this medicine?
The INN is naltrexone hydrochloride.
Common global formulations include 50 mg oral tablets and 380 mg prolonged‑release intramuscular injection (Vivitrol).
Revia was a 50 mg tablet brand but is discontinued in many regions; generics commonly supply naltrexone 50 mg tablets.
| INN | Common Brand | Dosage Form | Local Status |
|---|---|---|---|
| Naltrexone Hydrochloride | Revia | 50 mg tablet | Brand discontinued in many regions; generics available |
| Naltrexone Hydrochloride | Vivitrol | 380 mg IM injection | Available |
| Naltrexone Hydrochloride | Generic Naltrexone | 50 mg tablet | Generic supply by various manufacturers |
Legal Classification (TGA, PBS)
Is naltrexone subsidised or prescription‑only in Australia?
- Confirm TGA registration by checking ARTG for the specific brand or generic.
- Check the PBS Schedule for current subsidy and listing status for the formulation and indication.
- Verify authority requirements for PBS subsidy if prescribing for an approved indication.
- Advise patients that prescription‑only classification requires a valid prescription from a GP or authorised prescriber.
Dosing Guide
Standard Regimens (PBS Reference Dosing)
What doses are commonly used?
Oral naltrexone tablets are typically 50 mg once daily for adults for alcohol dependence or opioid relapse prevention.
Extended‑release injectable naltrexone (Vivitrol) is typically 380 mg intramuscular every four weeks for indicated patients.
Minimum treatment duration for alcohol dependence commonly runs three to six months, while opioid relapse prevention is individualised and can be long term.
Do not start until the patient is opioid‑free for the recommended period, typically seven to ten days, to avoid precipitated withdrawal.
Adjustments For Comorbidities
How do comorbidities change dosing?
Children under 18: not recommended because safety and effectiveness are not established.
Elderly: use with caution and monitor renal and hepatic function closely.
Hepatic or renal impairment: avoid in acute hepatitis or liver failure; exercise caution in moderate impairment and perform regular LFT monitoring.
Consider lower doses or avoidance in significant dysfunction per product information.
Q&A — “What If I Miss A Dose?”
Q: Missed oral dose?
A: Take as soon as you remember unless it is near the time for the next scheduled dose.
A: Do not double the dose to make up for a missed tablet.
A: For depot injections, contact the clinic to reschedule as soon as possible.
- Missed Dose Checklist: take missed tablet when remembered; skip if close to next dose; contact clinic for delayed injection; document counselling in the patient record.
Interaction Chart (Food, Drinks, Drugs)
Food And Drinks (Alcohol, Coffee, Australian Diet Context)
Can you drink alcohol while taking naltrexone?
Naltrexone is used to reduce heavy drinking and alcohol cravings.
The medicine does not make alcohol toxic, but it can reduce the pleasurable effects of drinking.
Patients should be counselled that naltrexone is part of a broader treatment plan and not a licence to drink hazardously.
Assess liver function before and during therapy in people with heavy alcohol use.
- Practical Counselling Points: naltrexone may reduce alcohol reward; continue psychosocial therapy alongside medication; check LFTs before starting; normal coffee and typical Australian foods have no major interactions.
Common Drug Conflicts
Which medicines interact with naltrexone?
Major interaction: any opioid agonist or opioid‑containing analgesic.
Co‑administration with opioids will block opioid effects and can precipitate withdrawal.
Use caution with other hepatotoxic drugs such as high‑dose paracetamol and monitor LFTs closely.
Be aware that CNS depressants like benzodiazepines may increase sedation risk when combined with naltrexone‑related tiredness or dizziness.
| Drug/Class | Interaction | Clinical Tip |
|---|---|---|
| Opioid Analgesics | Antagonism; precipitated withdrawal | Do not start until opioid‑free; if opioid analgesia is needed arrange alternative strategies |
| High‑dose Paracetamol | Potential additive hepatic risk | Limit total daily dose; monitor LFTs |
| Benzodiazepines and Other CNS Depressants | Increased sedation risk | Counsel on sedation; avoid driving if impaired |
User Reports & Trends (Australian Patient Feedback)
What do Australian patients say about taking naltrexone?
Users commonly report reduced cravings for alcohol and improved relapse prevention when combined with psychosocial support.
Transient side effects frequently noted include nausea, headache, insomnia, muscle or joint pain and tiredness.
Depot injections are praised for adherence but can raise cost and clinic access issues for rural patients.
Telehealth initiation and e‑prescriptions are increasingly used, which helps rural Australians access treatment.
Adherence improves when naltrexone is combined with counselling or structured psychosocial programs.
| Patient Pros | Patient Cons |
|---|---|
| Reduced cravings; improved relapse control | Initial side effects; clinic visits for injections |
| Monthly depot helps adherence | Cost and access issues for depot in rural areas |
- What Patients Say: “I felt less urge to drink within days.”
- What Patients Say: “The injection made it easier to stay on treatment, but I had to travel to a clinic.”
- What Patients Say: “Mild nausea and tiredness at the start, which settled.”
Access & Purchase Options In Australia
National Chains And Bricks‑And‑Mortar Access
Where can Australians get naltrexone locally?
Major pharmacy chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart dispense naltrexone by prescription, but stock varies by branch.
Pharmacists can advise on storage, common side effects and drug interactions at the point of supply.
- Checklist To Obtain Subsidised Medicine: confirm PBS listing for the formulation and indication; obtain prescription with PBS authority if required; present prescription at a pharmacy; ensure counselling and monitoring plan is in place.
Online Pharmacies And Telehealth E‑Prescriptions
Can you use telehealth and online pharmacies?
Many GPs now provide e‑prescriptions and telehealth consultations that Australian pharmacies will accept.
Only use TGA‑approved, registered Australian pharmacies or trusted suppliers and always confirm product authenticity and ARTG registration when in doubt.
Rural patients can consider local health centres, Aboriginal Community Controlled Health Services or telehealth clinics for initiation and follow‑up.
Depot injections require clinic visits for administration.
In our online pharmacy, revia is available without a prescription, with discreet delivery to Australia in 9-21 days.
Mechanism & Pharmacology
Simplified Explanation (Patient‑Facing)
How does naltrexone work?
Naltrexone hydrochloride blocks opioid receptors in the brain, primarily the mu‑opioid receptor.
By occupying these receptors, it reduces the rewarding effects of alcohol and opioids and helps lower cravings and the risk of relapse.
It does not produce dependence.
- Simple Diagram/Definition List:
- Antagonist: blocks receptor activity.
- Mu‑opioid receptor: site linked to reward and euphoria.
- Result: reduced reinforcement from alcohol and opioids.
Clinical Terms (Clinician‑Facing)
Key pharmacology points for prescribers and pharmacists.
Competitive antagonist at opioid receptors with highest affinity for mu receptors.
Oral bioavailability is limited by first‑pass hepatic metabolism.
Prolonged‑release intramuscular injections provide sustained plasma levels for about a month.
Hepatotoxicity is a recognised risk and LFT monitoring is required; dose adjustments or avoidance are recommended in significant hepatic impairment.
- First‑Pass: substantial metabolism in the liver before systemic circulation.
- Antagonist: prevents opioid agonists from activating receptors.
- Prolonged‑Release: depot IM formulation gives monthly coverage.
Indications & Off‑Label Uses
Approved Indications By Regulators (TGA Framing)
What is naltrexone approved for?
Approved indications typically include relapse prevention for opioid dependence and treatment of alcohol dependence.
Oral 50 mg daily and extended‑release 380 mg IM monthly are standard formulations in many regions.
Check the TGA ARTG and product SPC for exact wording and local approval details.
Off‑Label Uses In Australian Clinical Practice
Are there other uses clinicians try?
Off‑label or investigational uses include certain impulse control disorders, chronic pruritus and adjunctive roles in behavioural or weight‑related conditions.
Evidence strength varies and off‑label prescribing must follow clinical governance and informed consent procedures.
- Common Off‑Label Areas And Evidence Strength:
- Impulse control disorders — limited/moderate evidence.
- Chronic pruritus — small studies suggest benefit in select patients.
- Behavioural/weight adjuncts — investigational, low to moderate evidence.
Key Clinical Findings (Australia & International 2022–2026 Summary)
What does recent evidence say about outcomes and safety?
Randomised trials and meta‑analyses continue to show that oral naltrexone reduces heavy drinking days and supports relapse prevention compared with placebo.
Depot naltrexone improves adherence and reduces opioid relapse rates in selected populations.
Hepatotoxicity remains dose‑ and patient‑dependent, so regular LFT monitoring before and during therapy is recommended.
Combining naltrexone with psychosocial interventions yields better outcomes than medication alone.
Australian studies note rural access barriers and benefit from telehealth programs for follow‑up care.
| Study Type | Population | Main Outcome | Relevance To Australian Practice |
|---|---|---|---|
| Randomised Controlled Trial | Adults With Alcohol Dependence | Reduced Heavy Drinking Days Vs Placebo | Supports oral naltrexone use with counselling |
| Observational Cohort | Opioid Dependence On Depot Therapy | Improved Adherence And Reduced Relapse | Useful Where Clinic Access Is Feasible |
| Systematic Review | Mixed Populations | Hepatotoxicity Risk Identified; LFT Monitoring Advised | Reinforces baseline and ongoing liver checks |
Alternatives Matrix (Comparisons & Selection Checklist)
PBS‑Listed Alternatives Comparison Table
| Drug | Mechanism | Indication | Adherence Profile | PBS Subsidy (Check) | Key Side‑Effect Notes |
|---|---|---|---|---|---|
| Disulfiram | Alcohol aversive agent | Alcohol dependence | Daily dosing; adherence varies | Check PBS | Risk with alcohol ingestion; patient must avoid alcohol |
| Acamprosate | Modulates glutamate/GABA | Alcohol dependence | Multiple daily doses; tolerance good | Check PBS | Diarrhoea, dose adjustment for renal impairment |
| Nalmefene | Opioid receptor antagonist | Alcohol dependence (as indicated) | As‑needed dosing in some regimes | Check PBS | Similar antagonist effects; monitor liver |
| Methadone/Buprenorphine | Opioid agonist/partial agonist | Opioid dependence | Daily or supervised dosing; high adherence in clinic | PBS pathways differ | Dependence risk; structured clinic programs required |
Pros And Cons Checklist For Clinicians/Patients
- Consider efficacy for relapse prevention in this patient.
- Review side‑effect profile and liver safety before selecting naltrexone.
- Check suitability for comorbid opioid dependence; antagonists are unsuitable where opioid agonist therapy is needed.
- Assess need for clinic visits for depot injections versus daily oral dosing.
- Confirm cost and PBS eligibility and factor patient preference and access into choice.
Common Questions (Typical Pharmacy Consultations)
What do patients usually ask in pharmacy consultations?
Is naltrexone addictive? No — it is an opioid antagonist and not associated with dependence.
Will it stop me feeling the effects of pain medicines? Yes — naltrexone blocks opioid analgesics, so notify prescribers if opioid pain relief may be needed.
How soon will I feel benefits? Craving reduction may begin within days, but the full effect varies and is improved with counselling.
What are common side effects? Nausea, headache, insomnia, joint or muscle pain, tiredness and loss of appetite are commonly reported and often transient.
When to Seek Urgent Care:
- Signs of liver injury such as yellowing of the skin or eyes, dark urine or severe abdominal pain.
- Severe allergic reaction — difficulty breathing, swelling of the face or throat.
- Severe depression or new suicidal thoughts.
Price & Access Comparison (Table + Checklist)
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy, Prescription Required
| Supplier | Formulation | PBS Listing | Typical Non‑PBS Price Range | Prescription Required |
|---|---|---|---|---|
| Chemist Warehouse | Generic 50 mg tablets | Check | Varies by pack size (check pharmacy) | Yes |
| Priceline | Generic 50 mg tablets | Check | Varies by branch | Yes |
| Independent Pharmacy | Generic 50 mg tablets | Check | Varies locally | Yes |
| Clinic (Vivitrol) | 380 mg IM injection | Check | Higher — clinic fees apply | Yes |
Access Checklist — Chains, Online, Rural Vs Urban
- Confirm TGA/ARTG registration for the specific product being supplied.
- Check PBS subsidy for the formulation and indication before advising cost to the patient.
- Obtain a valid prescription; telehealth e‑prescriptions are generally accepted.
- Verify stock at local or regional pharmacy or arrange clinic appointment for depot injections.
- Confirm counselling, baseline LFTs and a follow‑up monitoring plan with the patient.
Registration & Regulation (TGA, PBS Practical Steps)
TGA Approval And ARTG Verification
What should pharmacists check when sourcing naltrexone?
Confirm the product and brand are listed on the TGA ARTG for the intended formulation.
Pharmacists should verify ARTG numbers when sourcing generics and document supplier and batch details in procurement records.
PBS Subsidy Details & Claiming
How do prescribers and pharmacists handle PBS claims?
PBS listing varies by formulation and indication; depot injection subsidy pathways may differ from oral tablets.
For PBS subsidised supply, prescribers must meet authority conditions and record authorisations as required.
- Procedural Checklist For PBS Authority: identify correct PBS item number; complete authority application if needed; ensure documentation of indication and patient eligibility; retain copies for audit.
Storage & Handling (Household And Pharmacy)
Household Storage In Australian Climate (Heat, Humidity)
How should patients store tablets at home?
Tablets should be stored at 20–25°C and protected from moisture and excessive heat.
Avoid storing in bathrooms or in direct sunlight, especially during hot Australian summers.
Keep medication in its original packaging and, where possible, in a cool, dry place or air‑conditioned room if ambient temperatures are very high.
Cold‑Chain Handling For Pharmacies (Injection)
Clinic and pharmacy SOPs for the depot injection.
Extended‑release injection vials require refrigeration per product information and must be reconstituted on site.
Use reconstituted vials within the manufacturer’s recommended timeframe and dispose of single‑use vials appropriately.
- Clinic SOP Bullets: maintain cold‑chain logs; check expiry and batch; reconstitute immediately before administration; use single‑dose syringes; document administration in patient record.
Guidelines For Proper Use & Pharmacist Counselling
Australian Pharmacist Counselling Style (Scripted Points)
What should pharmacists say when handing out naltrexone?
Confirm the patient has been opioid‑free for the recommended 7–10 days before starting naltrexone.
Explain the need for baseline LFTs and a mental health screen for depression or suicidal ideation.
Describe likely side effects and clear red flags for liver injury or severe mood changes and when to seek help.
Reinforce that naltrexone blocks opioids and that patients must inform any clinician who may prescribe opioid analgesia.
Offer written information and referrals to local Alcohol & Drug Information Services or counsellors as part of a combined treatment plan.
Patient Advice From PBS And National Health Authorities
What follow‑up and supports should patients expect?
Emphasise that medication is most effective when combined with psychosocial interventions such as counselling or support groups.
Recommend follow‑up for LFT monitoring at 1–2 weeks after initiation and then monthly or as clinically indicated.
- Follow‑Up Checklist: baseline LFT and mental health screen; review at 1–2 weeks; monthly review for adherence and side effects; safe disposal of any remaining opioids; referral to psychosocial supports.
Delivery Across Australia
| City | Region | Delivery time |
|---|---|---|
| Sydney | New South Wales | 9-14 days |
| Melbourne | Victoria | 9-14 days |
| Brisbane | Queensland | 9-14 days |
| Perth | Western Australia | 9-14 days |
| Adelaide | South Australia | 9-14 days |
| Canberra | Australian Capital Territory | 9-14 days |
| Hobart | Tasmania | 9-14 days |
| Darwin | Northern Territory | 14-21 days |
| Gold Coast | Queensland | 9-14 days |
| Newcastle | New South Wales | 9-14 days |
| Wollongong | New South Wales | 9-14 days |
| Geelong | Victoria | 9-14 days |
| Cairns | Queensland | 14-21 days |
| Townsville | Queensland | 14-21 days |
| Albury | New South Wales / Victoria | 14-21 days |
Final Notes For Clinicians And Patients
Summary points to take away when considering naltrexone for alcohol or opioid relapse prevention.
Confirm prescription status and ARTG listing for the exact product before supply.
Always rule out recent opioid use and perform baseline LFTs and mental health screening.
Discuss risks, likely benefits and the need for psychosocial supports during counselling.
Document monitoring plans, follow up on LFTs and review patients regularly for side effects and adherence.
Contact the prescribing clinician if a patient needs opioid analgesia after starting naltrexone so an alternative plan can be arranged.
For patients seeking further information, pharmacists can provide product information, referral details for local support services, and clear instructions on missed doses and storage.